A revolutionary development in the oncology field is the emergence of technologies that enable clinicians to rapidly screen for multiple cancer types using a single blood sample.
These tests, known as multi-cancer early detection (MCED) tests, are designed to detect circulating tumor biomarkers in the blood. And improve early detection, treatment, and outcomes for cancer patients.
Our latest whitepaper summarizes discussions between a panel of industry and academic leaders about the challenges and opportunities of MCED tests.
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
